Generic : Bendamustine
Trade name : Bimode
Strength : 100mg
Manufactured by : Emcure Pharmaceuticals
Packing : 1 injection in a vial
Bimode belongs to bifunctional mechlorethamine derivative accomplished of forming electrophilic alkyl groups which covalently bond to other molecules. Over this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death.
It is active against both active and quiescent cells, even though the exact mechanism of action is unknown.
Bimode is a prescription drug which is used under the guidance of medical supervision
Bimode 100mg is used for the treatment for Chronic lymphocytic Leukaemia in patients.
Bimode 100mg is used for the treatment for Indolent B-cell non-Hodgkin’s lymphoma in patients
For chronic lymphocytic Leukaemia: The Bimode usual dose is 100mg/m2 IV infusion on days 1 and 2 of 28-day cycle, repeated for up to 6 cycles
Non-Hodgkin Lymphoma: The Bimode usual dose is 120mg/m2 IV infusion on days 1 and 2 of 21-day cycle repeated for up to 8 cycles
MECHANISM OF ACTION
Bendamustine belongs to alkylating agent, a chemical which can be internalized by cell and cause abnormal bonds between strands of DNA. This is an irreversible process which inhibits the cell from replicating and causes the affected cell to die.
Bendamustine works in both cancerous and healthy cells.
Time to peak plasma: At end of infusion
Protein bound: 94-96%
Volume of distribution: 25L
Metabolized by CYP1A2
Excretion: feces 90%; Urine 1-10%
Serious infusion and anaphylactic reactions resulted; check clinically and stops treatment; premeditate in consecutive cycles for milder reactions
While on treatment will causes tumor lysis syndrome occurs; acute renal failure and death may reported; anticipate and use supportive measures
Probably of anaphylactic/infusion reactions: serious in rare cases
Myelosuppression may report; decrease dose; restart treatment based on ANC and platelet count recovery; difficult situation of myelosuppression may lead to death
Check further fever and other signs of infection and treat promptly.
Bimode co administration with CYP1A2 inhibitors will have probably to increase plasma concentration of bendamustine and decrease plasma concentration of active metabolites.
Bimode co administration with CYP1A2 inducers will have probably to decrease plasma concentration of bendamustine and increase plasma concentration of active metabolites.
Known hypersensitivity to bendamustine and its metabolites
Store in refrigerator at 2℃ to 8℃
keep in original containers until time of use.
If dose is missed, then have immediately before the reaching of next dose time or swap the missed dose and continue regular schedule. Consult the doctors for more information
Common side effects :
Decreased blood counts
Some rare side effects :